Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,937 matching trials from the live ClinicalTrials.gov search.
Conditions
Limbal Stem Cell Deficiency
Interventions
LSC2
Biological
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

NCT07694492
Conditions
Tobacco Use Cessation, Tobacco Use Disorder, Nicotine Dependence, Smokeless Tobacco Use
Interventions
QuitAid (pharmacist-delivered MTM), Nicotine Replacement Therapy (NRT)
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cigarette Smoking, E-cigarette Use
Interventions
Nicotine Content, Illegal cigarette price, E-cigarette price
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Completed Not applicable Interventional Results available

HIV/STI Prevention for Drug-Involved Couples

NCT01285349
Conditions
Sexually Transmitted Infections
Interventions
Couple HIV/STI prevention intervention, Couple-based HIV/STI prevention, Individual HIV/STI prevention, Couple Wellness Promotion
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 40 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Conditions
Asthma in Children
Interventions
Inulin
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Pancreatic Fistula
Interventions
Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Kerendia (Finerenone, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Phase 2 Interventional Results available

Polypill in Acute Coronary Syndrome

NCT05514938
Conditions
Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions
Polypill, Usual Care (individual medications prescribed by primary cardiologist)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Withdrawn No phase listed Observational

Hearing Changes After Surgery

NCT04322747
Conditions
Hearing Loss
Interventions
Distortion product otoacoustic emissions (DPOAE)
Diagnostic Test
Lead sponsor
Gateway Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Conditions
Healthy Adults
Interventions
Real-Time Myocardial Echocardiography (RTMPE), Magnetic resonance image (MRI)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Reducing High Risk Behavior in Treatment Court

NCT01481428
Conditions
Substance Abuse, HIV
Interventions
Computer-facilitated HIV intervention, Attention Control
Behavioral
Lead sponsor
Treatment Research Institute
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Colorectal Cancer
Interventions
Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Active by Choice Today (ACT) Trial to Increase Physical Activity

NCT01028144
Conditions
Exercise, Physical Activity, Obesity
Interventions
Physical Activity Program, General Health Program
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
10 Years to 13 Years
Enrollment
1,422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Columbia, South Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
75 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
176
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy of Using Solum IV and BMC With GFC in TLIF

NCT03223701
Conditions
Degenerative Disc Disease, Isthmic-lytic Spondylolisthesis, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion
Combination Product
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Pain
Interventions
Breast Human Milk, 24 % Sucrose
Other
Lead sponsor
Wayne State University
Other
Eligibility
1 Day to 30 Days
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Factor VIII Deficiency
Interventions
efanesoctocog alfa (BIVV001)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
Completed Not applicable Interventional Results available

Rifaximin in Minimal Hepatic Encephalopathy

NCT00533910
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, placebo
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls

NCT01813123
Conditions
Drug Abuse Prevention
Interventions
RealTeen
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 14 Years · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York